2-chloro-N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-furan-2-yl-pyramidin-4-yl]-acetamide | 1006381-07-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-chloro-N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-furan-2-yl-pyramidin-4-yl]-acetamide
• 英文别名: 2-Chloro-N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-furan-2-yl-pyrimidin-4-yl]-acetamide；2-chloro-N-[6-(3,5-dimethylpyrazol-1-yl)-2-(furan-2-yl)pyrimidin-4-yl]acetamide
• CAS: 1006381-07-2
• 化学式: C₁₅H₁₄ClN₅O₂
• 分子量: 331.761
• InChiKey: GBEUIYIKRLZPHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-甲基哌嗪 、 2-chloro-N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-furan-2-yl-pyramidin-4-yl]-acetamide 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以76%的产率得到N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(furan-2-yl)pyrimidin-4-yl)-2-(4-methylpiperazin-1-yl)acetamide
  参考文献：
  名称：

  Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl Acetamides as A_2A Receptor Antagonists with In Vivo Efficacy

  摘要：

  Potent adenosine hA(2A) receptor antagonists are often accompanied by poor aqueous solubility, which presents issues for drug development. Herein we describe the early exploration of the structure-activity relationships of a lead pyrimidin-4-yl acetamide series to provide potent and selective 2-amino-N-pyrimidin4-yl acetamides as hA(2A) receptor antagonists with excellent aqueous solubility. In addition, this series of compounds has demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's disease, despite having reduced potency for the rat A(2A) receptor versus the human A2A receptor.

  DOI：

  10.1021/jm070623o
• 作为产物：
  描述：

  6-(3,5-dimethyl-pyrazol-1-yl)-2-furan-2-yl-pyramidin-4-ylamine 、 氯乙酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-chloro-N-[6-(3,5-dimethyl-pyrazol-1-yl)-2-furan-2-yl-pyramidin-4-yl]-acetamide
  参考文献：
  名称：

  Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl Acetamides as A_2A Receptor Antagonists with In Vivo Efficacy

  摘要：

  Potent adenosine hA(2A) receptor antagonists are often accompanied by poor aqueous solubility, which presents issues for drug development. Herein we describe the early exploration of the structure-activity relationships of a lead pyrimidin-4-yl acetamide series to provide potent and selective 2-amino-N-pyrimidin4-yl acetamides as hA(2A) receptor antagonists with excellent aqueous solubility. In addition, this series of compounds has demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's disease, despite having reduced potency for the rat A(2A) receptor versus the human A2A receptor.

  DOI：

  10.1021/jm070623o

文献信息

• Substituted Pyrimidines as Adenosine Receptor Antagonists
  申请人：Slee Deborah

  公开号：US20080275064A1

  公开（公告）日：2008-11-06

  Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.

  式(I)的化合物，包括药学上可接受的盐、酯、溶剂合物和立体异构体，其中R1、R2和R3的定义如本文所述。含有式(I)化合物的制药组合物，以及与其使用作为腺苷受体拮抗剂相关的方法，特别是A2A腺苷受体亚型的拮抗剂。
• 2-Amino-<i>N</i>-pyrimidin-4-ylacetamides as A_2A Receptor Antagonists: 1. Structure−Activity Relationships and Optimization of Heterocyclic Substituents
  作者：Deborah H. Slee、Yongsheng Chen、Xiaohu Zhang、Manisha Moorjani、Marion C. Lanier、Emily Lin、Jaimie K. Rueter、John P. Williams、Sandra M. Lechner、Stacy Markison、Siobhan Malany、Mark Santos、Raymond S. Gross、Kayvon Jalali、Yang Sai、Zhiyang Zuo、Chun Yang、Julio C. Castro-Palomino、María I. Crespo、Maria Prat、Silvia Gual、José-Luis Díaz、John Saunders

  DOI：10.1021/jm701185v

  日期：2008.3.1

  Previously we have described a novel series of potent and selective A(2A) receptor antagonists (e.g., 1) with excellent aqueous solubility.(1) While these compounds are efficacious A(2A) antagonists in vivo, the presence of an unsubstituted furyl moiety was a cause of some concern. In order to avoid the potential metabolic liabilities that could arise from an unsubstituted fury] moiety, an optimization effort was undertaken with the aim of replacing the unsubstituted furan with a more metabolically stable group while maintaining potency and selectivity. Herein, we describe the synthesis and SAR of a range of novel heterocyclic systems and the successful identification of a replacement for the unsubstituted furan moiety with a methylfuran or thiazole moiety while maintaining potency and selectivity.
• 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Almirall, S.A.

  公开号：EP1888565B1

  公开（公告）日：2011-03-23
• [EN] SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] PYRIMIDINES SUBSTITUEES UTILISEES COMME ANTAGONISTES DU RECEPTEUR D'ADENOSINE
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2006110884A2

  公开（公告）日：2006-10-19

  (EN) Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, Rl, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine receptor subtype.(FR) Cette invention concerne des composés représentés par la formule (I), y compris des sels, esters, solvates, stéréo-isomères et promédicaments de ceux-ci, R1, R2 and R3 étant définis dans la demande. Des compositions pharmaceutiques contenant un composé de structure (I) ainsi que des procédés relatifs à l'utilisation de ces compositions sont également décrits.